Daratumumab for the treatment of multiple myeloma.
Touzeau C et al. Expert Opin Biol Ther. 2017 Apr 24. doi: 10.1080/14712598.2017.1322578. [Epub ahead of print].

New developments in the treatment of multiple myeloma – clinical utility of daratumumab.
McEllistrim C et al. Biologics. 2017 Apr 11;11:31-43. doi: 10.2147/BTT.S97633. eCollection 2017.

Immunologic approaches for the treatment of multiple myeloma.
Rasche L et al. Cancer Treat Rev. 2017 Apr 6;55:190-199. doi: 10.1016/j.ctrv.2017.03.010. [Epub ahead of print].

Which therapies will move to the front line for multiple myeloma?
Cejalvo MJ et al. Expert Rev Hematol. 2017 Apr 24:1-10. doi: 10.1080/17474086.2017.1317589. [Epub ahead of print].

Transplantation for Myeloma – Now or Later?
Schiffer CA et al. N Engl J Med. 2017 Apr 6;376(14):1378-1379. doi: 10.1056/NEJMe1700453.

Long-term stabilisation of myeloma with curcumin.
Zaidi A et al. BMJ Case Rep. 2017 Apr 16;2017. pii: bcr2016218148. doi: 10.1136/bcr-2016-218148.

Emergency diagnosis of cancer and previous general practice consultations: insights from linked patient survey data.
Abel GA et al. Br J Gen Pract. 2017 Apr 24. pii: bjgp17X690869. doi: 10.3399/bjgp17X690869. [Epub ahead of print].

The Molecular Mechanisms of Thalidomide Teratogenicity and Implications for Modern Medicine.
Knobloch J et al. Curr Mol Med. 2017 Mar 31. doi: 10.2174/1566524017666170331162315. [Epub ahead of print].

Age-related health care disparities in multiple myeloma.
Puyade M et al. Hematol Oncol. 2017 Apr 21. doi: 10.1002/hon.2422. [Epub ahead of print].

Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis.
Thoennissen GB et al. Acta Haematol. 2017 Apr 12;137(3):163-172. doi: 10.1159/000463534. [Epub ahead of print].

IgM Myeloma: A Multicenter Retrospective Study of 134 Patients.
Castillo JJ et al. Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24753. [Epub ahead of print].

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC et al. Clin Cancer Res. 2017 Apr 20. pii: clincanres.2895.2016. doi: 10.1158/1078-0432.CCR-16-2895. [Epub ahead of print].

Statin use and risk of multiple myeloma: An analysis from the Cancer Research Network.
Epstein MM et al. Int J Cancer. 2017 Apr 20. doi: 10.1002/ijc.30745. [Epub ahead of print].

Stem cell transplantation in multiple myeloma.
Das M. Lancet Oncol. 2017 Apr 13. pii: S1470-2045(17)30276-0. doi: 10.1016/S1470-2045(17)30276-0. [Epub ahead of print].

Study design for vulnerable older adults with multiple myeloma.
Nathwani N et al. J Geriatr Oncol. 2017 Apr 12. pii: S1879-4068(17)30033-4. doi: 10.1016/j.jgo.2017.02.007. [Epub ahead of print].

Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey.
Merz M et al. Ann Hematol. 2017 Apr 13. doi: 10.1007/s00277-017-2991-0. [Epub ahead of print].

Dementia and multiple myeloma.
Jolobe OM. Br J Hosp Med (Lond). 2017 Apr 2;78(4):236. doi: 10.12968/hmed.2017.78.4.236.

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.
Chhabra S. Pharmaceuticals (Basel). 2017 Apr 11;10(2). pii: E40. doi: 10.3390/ph10020040.

End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.
Hoering A et al. Future Oncol. 2017 Apr 11. doi: 10.2217/fon-2016-0504. [Epub ahead of print].